Baiao Analytical Biosciences Complete Series A Financing

Single cell genome research company Baiao Analytical Biosciences just completed Series A financing, this round of financing was led by IDG Capital. The funds will be used to accelerate the research of single-cell genomics in human medicine, especially the establishment of single-cell big data platforms and intelligent analysis programs.

The founding team of Baiao Analytical Biosciences has a background in genomics, bioinformatics, ICT and investment. Experienced in the biotechnology, pharmaceutical and other industries. Professor Zemin Zhang, founder and scientific consultant, has been a chief scientist in the bioinformatics department at Genentech for a long time. He is an internationally renowned tumor genomics scientist.

With the rapid development of single-cell sequencing technology and the rapid accumulation of data, it is the competitiveness of future genomic medical companies to have the ability to efficiently process massive amounts of data and to effectively interpret single-cell big data.

Founded in 1992, IDG Capital is an investment firm that funds early- to growth-stage companies in the technology sector in China.